Phase I study of cisplatin and irinotecan combined with concurrent hyperfractionated accelerated thoracic radiotherapy for locally advanced non-small cell lung carcinoma
| Autor: | Reiko Uruma, Takayuki Kuriyama, Yuichi Takiguchi, Yoshiko Asaka-Amano, Takashi Uno, Nobuhiro Tanabe, Hisao Itoh, Koichiro Tatsumi, Yasunori Kasahara, Katsushi Kurosu |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Male
Oncology medicine.medical_specialty Lung Neoplasms Maximum Tolerated Dose medicine.medical_treatment Irinotecan Carcinoma Non-Small-Cell Lung Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Esophagitis Humans Combined Modality Therapy Survival rate Aged Cisplatin Performance status business.industry Dose fractionation Hematology General Medicine Middle Aged Survival Rate Radiation therapy Camptothecin Female Surgery Dose Fractionation Radiation business Chemoradiotherapy medicine.drug |
| Zdroj: | International Journal of Clinical Oncology. 10:418-424 |
| ISSN: | 1437-7772 1341-9625 |
| Popis: | Irinotecan, when combined with cisplatin, is an effective treatment for advanced non-small cell lung cancer (NSCLC). This constitutes a rationale for conducting a phase I study of chemoradiotherapy including this combination for locally advanced NSCLC.Patients with locally advanced NSCLC and a performance status of 0 or 1 were eligible. The protocol consisted of escalating doses of irinotecan on days 1 and 15, and daily low-dose cisplatin (6 mg/m(2) daily for a total dose of 120 mg/m(2)) combined with concurrent hyperfractionated accelerated thoracic irradiation (1.5 Gy twice daily for a total dose of 60 Gy).The maximum tolerable dose was 50 mg/m(2) of irinotecan, and the dose-limiting toxicity was esophagitis. Tumor response was observed in 50% of cases, and the median survival time of the 12 patients enrolled was 10.1 months, including two patients with 5-year disease-free survival. A pharmacokinetics study demonstrated an accumulation of total platinum, but not of free platinum, during the 26-day treatment period.The recommended dose for phase II studies was determined. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink